绝经后早期接受辅助芳香酶抑制剂治疗的乳腺癌女性的睡眠障碍和不宁腿综合征。
Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy.
机构信息
Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy; SSVD Breast Unit, ASST-Spedali Civili of Brescia, Brescia, Italy.
Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy.
出版信息
Breast. 2022 Dec;66:162-168. doi: 10.1016/j.breast.2022.10.006. Epub 2022 Oct 18.
INTRODUCTION
Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue.
METHODS
Between March 2014 and November 2017, validated questionnaires for assessing insomnia, anxiety, depression, quality of life (QoL) and restless legs syndrome (RLS) were administered to 160 EBC patients at baseline and after 3, 6, 12, and 24 months of AI therapy.
RESULTS
AI therapy significantly decreased the patients' QoL, but did not influence insomnia, anxiety or depression. However, it significantly increased the frequency and severity of RLS. Patients with RLS at baseline (19%) or who developed RLS during AI therapy (26.3%) reported statistically lower quality of sleep, higher anxiety and depression, and worse QoL compared to patients who never reported RLS (54.7%).
CONCLUSION
Although AI therapy does not affect sleep quality, it may increase RLS frequency. The presence of RLS could identify a group of EBC patients who may benefit from psychological support.
简介
芳香化酶抑制剂（AIs）辅助治疗是否会引起绝经后早期乳腺癌（EBC）女性的睡眠障碍，仍是一个有争议的问题。
方法
2014 年 3 月至 2017 年 11 月，对 160 例接受 AI 治疗的 EBC 患者在基线和治疗后 3、6、12 和 24 个月时进行了评估失眠、焦虑、抑郁、生活质量（QoL）和不宁腿综合征（RLS）的有效问卷。
结果
AI 治疗显著降低了患者的 QoL，但对失眠、焦虑或抑郁无影响。然而，它显著增加了 RLS 的频率和严重程度。基线时有 RLS（19%）或在 AI 治疗期间发生 RLS（26.3%）的患者报告的睡眠质量、焦虑和抑郁程度以及 QoL 均明显低于从未报告 RLS（54.7%）的患者。
结论
尽管 AI 治疗不会影响睡眠质量，但它可能会增加 RLS 的频率。RLS 的存在可以确定一组可能受益于心理支持的 EBC 患者。
Zotero 插件